After posting 16.2% revenue growth in the last financial year, Servier President Olivier Laureau said the company has moved “one important step closer” to achieving an ambitious goal for 2030.
Total revenues of 6.9 billion euros ($8.2 billion) for the 2024-25 financial year have given Servier confidence in its ability to achieve 10 billion euros ($12 billion) in annual sales by 2030, the company said Tuesday. Servier’s financial year ends in September.
The most recent annual haul handily surpassed Servier’s previous target of 6 billion euros. Oncology revenues, which reached 2.2 billion euros, were cited as the group’s main growth driver.
Benefiting from the 2024 rollout of the IDH1/2 inhibitor Voranigo in low-grade glioma in the U.S., Servier’s oncology business chalked up a 55% growth in the 2024-25 financial year. The department’s revenue contribution to the entire group rose to 32%, compared with 24% the previous year. Voranigo was approved in EU in September toward the end of Servier’s fiscal cycle.
As oncology continues to serve as Servier’s main growth engine, the company, in its Jan. 27 press release, also highlighted an ambition to establish a “leading neurology franchise by developing a robust pipeline in rare neurological diseases modeled on its oncology strategy.”
Toward that goal, Servier in September made the company’s first asset acquisition in neurology, buying a candidate for fragile X syndrome, the most common genetic cause of autism, from Kaerus Bioscience.
RELATED
Servier supercharges neuro pipeline with $450M deal for fragile X syndrome candidate
Servier’s neurology pipeline currently comprises eight early research projects and three clinical programs. Last year, citing its 2030 strategy, the company brought on Nitza Thomasson, Ph.D., to lead neurology R&D.
“Leveraging the strength of its global resources, Servier also intends to become a partner of choice for innovative biotech companies in the development of new drugs that slow or halt the progression of rare neurological disorders and significantly improve patient quality of life,” the company said in the release.
Still, on the dealmaking front, Servier has been more active in oncology. Last year alone, the French pharma licensed a phase 1 asset from Black Diamond Therapeutics for RAF/RAS-mutant solid tumors, acquired a phase 1/2 leukemia candidate from BioNova Pharmaceuticals and obtained ex-U.S. rights to Ideaya Biosciences’ potential first-in-class PKC inhibitor darovasertib, which is being developed in uveal melanoma.
Then, at the beginning of 2026, Servier unveiled an oncology drug discovery pact with artificial intelligence biotech Insilico Medicine.
RELATED
Insilico, fresh off its Hong Kong IPO, pens potential $888M cancer R&D pact with Servier
As for the third pillar of Servier’s innovative drugs business, cardiometabolic therapies accounted for 43% of the company’s revenues in 2024-25. The performance was fueled by venous circulation disorders therapy Daflon and single-pill combinations.
Even as Servier targets 10 billion euros in annual sales by 2030, the company's operating structure is morphing. The 2030 target includes 2 billion euros in contributions from generic medicines, which delivered nearly 1.6 billion euros in the 2024-25 financial year. But, in July, Servier announced exclusive negotiations to sell its generic drug subsidiary, Biogaran, to BC Partners.
“[T]he proceeds from this transaction should enable Servier to accelerate its focus, particularly on innovative treatments in oncology and neurology, and to continue creating value in France,” Laureau said in a statement July 30.